HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauren Nardella

Lauren Nardella covers health care business topics, including contributions for more than a decade to HBW Insight (and previously the Rose Sheet) for more than a decade, where’s she has covered the regulation, business, science and policy of the cosmetics and personal-care products industries. She enjoys tackling complex issues and turning them into stories that help readers stay abreast of current topics. Nardella was previously a business reporter for various daily newspapers. She lives in Northern Virginia.

Latest From Lauren Nardella

Canada Responds To Children’s OTC Pain Reliever Shortage Linked To Consumers ‘Panic Buying’

Shortage began in August and has increased the onset of cough/cold season due to consumers’ “stockpiling/panic buying” in response to high levels of activity in COVID-19, RSV, seasonal flu and other viruses, according to Canadian Pharmacists Association. Health Canada has approved imports of Haleon and J&J children’s pain relievers.

Coronavirus COVID-19 OTC Drugs

PCPC Raises ‘Grave Concerns’ About China’s Cosmetic Regs, Possible WHO Treaty Noncompliance

Foreign cosmetic product manufacturers may avoid the Chinese market if burdensome registration requirements aren’t modified and fairness issues addressed, the trade association says in comments to the Office of the US Trade Representative.

Regulation China

20 Democrat, 1 GOP State AGs Frame OTC Birth Control Within Protecting Reproductive Rights

Citing national uncertainty regarding reproductive health care – “ a time when reproductive rights have been curtailed across the country – state AGs urge FDA to approve OTC birth control proposal from HRA Pharma.

Prescription To OTC Switch Drug Approval Standards

OTC Birth Control Not Good For Women's Health, Natural Family Planning Group Says

SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”

Prescription To OTC Switch FDA

Opill Proposal Makes ACNU Sense, Stakeholders Comment On US 'Additional Conditions' Proposal

As pharma marketing and Rx-to-OTC switch experts told HBW Insight, health care industry stakeholders submitting comments to the FDA connect Opill NDA to FDA’s consideration of an ACNU pathway.

Prescription To OTC Switch Drug Approval Standards

Sanofi Eyes Using Zantac 360 Most-Recommended Ad Claim With Disclaimer Highlighting Ingredient

Industry self-regulation group’s appeals board agrees with investigative division’s finding Sanofi didn’t support Zantac 360 “#1 doctor recommended” ad claims. Board declines to consider whether “#1 doctor recommended H2 active ingredient” with “based on generic acid reducer recommendations” disclaimer is supported.

Advertising, Marketing & Sales Enforcement
See All
UsernamePublicRestriction

Register